KRAS

News

Spinning top in black and white, revolving

Report says MSD is in talks to buy Revolution Meds

MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.

News

Bayer buys into KRAS with $1.3bn Kumquat deal

Bayer has joined the throng of drugmakers developing KRAS-targeting therapies for cancer, via an alliance with San Diego biotech Kumquat.

Oncology

AACR 2025: New modalities and remaining challenges

Explore the latest advancements and challenges in ADC therapy at AACR 2025: New modalities and remaining challenges

News

Amgen picks up key colorectal cancer okay for KRAS drug

Can a new FDA approval in colorectal cancer kickstart sales growth for Amgen's KRAS inhibitor Lumakras?

News

BMS gets FDA approval for Krazati in colorectal cancer

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product.

News

ASCO: KRAS upstarts set their sights on NSCLC market

There are already two drugs on the market targeting KRAS mutations, for decades considered an undruggable target, but no shortage of drug candidates hoping to follow them.

Report says MSD is in talks to buy Revolution Meds

Bayer buys into KRAS with $1.3bn Kumquat deal

AACR 2025: New modalities and remaining challenges

Amgen picks up key colorectal cancer okay for KRAS drug

BMS gets FDA approval for Krazati in colorectal cancer

ASCO: KRAS upstarts set their sights on NSCLC market

J&J jumps on the MFN pricing train

How to meet your physicians where they are online

KRAS

Editor's Picks